Andrew Mok

There's been a lot of developments in the GLP-1 market, including your announced partnerships with Lilly and Novo this quarter

As the Part D market evolves alongside the IRA, curious to hear what your experience has been on the EverNorth side of the business

can you share how you're thinking about pricing for 2027 and the balance between further margin recovery

Can you help us understand why you believe you attracted that higher acuity cohort for this year

the guide seems to imply incremental pressure within Medicare Advantage beyond the PDP reset

help clarify and level set the expectations for margin improvement next year

You help us understand how the risk corridor actually works? Is that applied at the contract level or plan level

I wanted to revisit your assumption that ACA membership could be down 20% to 30% if enhanced APTCs expire. Are buydowns contemplated within that assumption

can you help us understand the level and pace of AI investments you're making this year

Your medical membership was revised up 200,000 members, even though AEP results were described as being consistent

I wanted to ask about the recontracting efforts at Oak Street and understand the room for improvement there

Can you help reconcile your favorable Medicare results in the HCB segment with the unfavorable results you're seeing at Oak Street

Wanted to follow up on your comments at Oak Street, where you noted some early signs of pressure. Can you elaborate on the nature and timing

you also took aggressive actions on the individual ACA business, so was hoping you could elaborate on those actions

Is it your sense that industry volumes were negative or did smaller chains take market share?

Hoping you could provide more color on what you're doing to position yourself to capture market share

any color on the underlying mortality performance would be helpful considering that's an important metric for building consensus on volumes for the balance of the year?

Can you help us understand how missed treatments and mortality trended throughout the fourth quarter?

Can you give us more detail on how you expect the ACA headwind to play out this year from a cadence perspective?

I think the last estimate of the headwind you gave was $120 million over 3 years. Is that still a good number to think about?

is it fair to think of that as a reasonable starting point as we contemplate potential growth for next year?

can you give us the phosphate binder contribution to RPT and CPT in the quarter? And why was the dispensing volumes lower in the quarter?

Can you give us a sense for how census and treatments track following the cyber attack and how you're thinking about volumes in the back half?

Are you going to adjust that out of earnings, or will you be incurring those costs and absorbing that into guidance?

can you help us understand how much of that was attributable to flu in the first quarter and how much of that is attributable to the cyberattack?

can you provide a bit more color on what you saw in the quarter with respect to uptake and drug mix?

that feels a little bit light versus what CMS quantified today in the final rate. So just trying to understand the absolute dollars on the Medicare patients specifically

You called out $0.25 of favorability this quarter, which grew sequentially from $0.15 in the first quarter.

have you observed any impact from higher gas prices or broader macro pressures on health care utilization

You commented that you now expect Medicare operating margins to increase slightly in '25, but I think it was unclear if that was a year-over-year comment or a positive revision to this year's outlook

Can you help delineate the pressure you're seeing in that business between unit cost trends and shifts in the risk pool

Can you help us understand what developed favorably in the back half of March to drive that better MLR performance

I was hoping you could clear some of this up and tell us what your actual AEP growth is, and how much of that accounts for the full year outlook

Can you clarify how many quarters worth of Florida DPP were recognized in the quarter itself?

Last quarter, you called out a few underperforming regions outside the hurricane markets. Can you give us an update on those markets

Hoping you could spike out the performance of Mission Hospital in the quarter and help us understand what impacts that had on same-store volumes in the quarter

would love to hear your perspective on the recent litigation outcomes around the MA Stars program

do you plan to exercise your June call options for the first 2 clinic cohorts?

I was hoping you'd be able to offer a framework for the level of new growth that you're comfortable with before it starts to impact your operational capacity

One of your peers noted a pretty meaningful pullback in the individual PPO market next year. Just curious how you're thinking about the implications

Can you provide more color on your experience in Part D relative to expectations? And specifically, can you comment on the pace that seniors are tracking

Can you share the splits of the incremental STARS investments across the MLR and OpEx line?

can you comment on volume progression throughout the quarter in each segment, including exit rates in March and April?

Can you give us a bit more detail on the nature of the headwind and help us understand why the headwind from the midyear implementation wouldn't annualize into a larger run rate headwind?

outside of the discrete items related to state directed payments in Cedar Hill, the EBITDA guidance looks largely unchanged. One, do I have that right?

You called out $25 million of start-up losses in the quarter. Can you update us on the latest accreditation status of that hospital?

are you seeing any changes in your behavioral referral patterns or willingness of JV partners to work with UHS

Can you help us understand what actions you're taking now to prepare for potential tariffs? And what your GPO has communicated to you thus far?

The 2025 EBITDA guidance is up 5% to 11%, which is higher than typical growth rates this despite state supplemental payments forecasted to be down year over year

Could you help us unpack what's driving the outperformance in Optum Health this quarter?

Can you elaborate on your experience with the co-pay structure in 2025? And what drove that decision to change the benefit structure in 2026?

Can you compare the relative margin profiles and different paths of margin recovery for each including which population is most addressable near term

I was hoping to get your thoughts on the risks and implications of tariffs, particularly around the impact of pharmaceutical tariffs